ReviewJournal of fluorescence2026
Application of Quantum Dot Multimodal Imaging in Early Disease Diagnosis.
Review in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Quantum dot-based multimodal imaging technology provides a highly sensitive and versatile detection approach for early disease screening, demonstrating significant clinical value. This technology simultaneously offers high-sensitivity optical signals, superior tissue penetration depth, and precise anatomical localization, overcoming the inherent limitations of single-modal imaging. This review focuses on the applications and advantages of this technology in early disease screening, particularly highlighting its synergistic applications in fluorescence imaging (enabling high-precision multichannel detection), magnetic resonance imaging (MRI) (where controlled doping strategies facilitate dual-mode contrast enhancement), and computed tomography (CT) (where high-atomic-number quantum dot contrast agents surpass traditional sensitivity limits). Furthermore, the functionalized surface modification of quantum dots enables targeted delivery and therapeutic capabilities, along with artificial intelligence assisted quantum dots data analysis, promoting theranostic integration. Future advancements are expected to further optimize imaging precision and expand clinical applications, offering revolutionary tools for early disease diagnosis with broad development prospects.
Indexed as
Identifiers
41139377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.